U.S. markets open in 2 hours 3 minutes
  • S&P Futures

    3,708.00
    -24.00 (-0.64%)
     
  • Dow Futures

    29,611.00
    -139.00 (-0.47%)
     
  • Nasdaq Futures

    11,447.25
    -108.50 (-0.94%)
     
  • Russell 2000 Futures

    1,709.20
    -11.60 (-0.67%)
     
  • Crude Oil

    82.56
    +0.41 (+0.50%)
     
  • Gold

    1,659.00
    -11.00 (-0.66%)
     
  • Silver

    18.69
    -0.18 (-0.98%)
     
  • EUR/USD

    0.9725
    -0.0014 (-0.15%)
     
  • 10-Yr Bond

    3.7050
    0.0000 (0.00%)
     
  • Vix

    31.52
    -1.08 (-3.31%)
     
  • GBP/USD

    1.0857
    -0.0028 (-0.26%)
     
  • USD/JPY

    144.6600
    +0.5380 (+0.37%)
     
  • BTC-USD

    19,506.36
    +593.51 (+3.14%)
     
  • CMC Crypto 200

    445.88
    +17.10 (+3.99%)
     
  • FTSE 100

    6,952.70
    -52.69 (-0.75%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

Jupiter Wellness Seeks New Prescription Products For Issues In Breast Cancer Patients

·1 min read
  • Jupiter Wellness Inc (NASDAQ: JUPW) has signed an exclusive licensing agreement with Rejoy Inc to develop prescription products for the treatment of nipple neuropathies for breast cancer patients.

  • The exclusive license includes issued patents and technology, including formulations.

  • RelatedJupiter Wellness Registers 400% Jump In Q2 Revenue

  • In clinical studies, one topical formulation improved nipple sensitivity and alleviated associated sexual problems.

  • The product has been named JW-500 to be added to a line of other clinical stage products currently under development.

  • Jupiter Wellness plans to file for a pre-IND meeting with the FDA within the next 12 months and intends to seek Orphan Drug Designation.

  • Price Action: JUPW shares are trading higher by 1.63% at $1.05 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.